Physician profile
Nirmala R Tummalapenta
NPI 1346381183
$16,037.40
in general payments reported to CMS, 2019-2025
46 companies · $2,957 in 2025
The $2,957 reported for 2025 was more than what 96% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $1,203 · 2021: $2,515 · 2022: $2,691 · 2023: $2,682 · 2024: $2,893 · 2025: $2,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,447 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,446.67 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,723.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $2,242.78 | 2019-2025 | Fasenra, Farxiga, Breztri |
| Abbvie INC. | $1,362.36 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $1,313.77 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $1,244.50 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $1,199.09 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Exact Sciences Corporation | $599.34 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $563.39 | 2021-2024 | Xifaxan |
| Astellas Pharma US INC | $539.78 | 2019-2025 | Veozah, Myrbetriq, Vesicare |
| Esperion Therapeutics, INC. | $534.61 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $502.29 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $452.24 | 2023-2025 | Caplyta |
| Abbott Laboratories | $295.13 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $279.06 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $260.95 | 2019-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirmala Tummalapenta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.